Enterprise Value
-93.46M
Cash
131.5M
Avg Qtr Burn
-12.11M
Short % of Float
0.35%
Insider Ownership
5.88%
Institutional Own.
50.86%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATL001 (TIL cNeT) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Data readout | |
ATL001 (cNeT) +/- Nivolumab (anti-PD-1) Details Melanoma, Cancer, Solid tumor/s | Phase 1/2 Data readout |